From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
STAT News · LC · trust 42/100
Biotech companies are racing to cure alpha-1 antitrypsin deficiency, AATD, fueling patent disputes, startup defections, arbitration, and a U.S.-China rivalry.
Read the original at STAT News →
Open in TruthVane →